Latest News
Can-Fite reports preclinical data supporting Phase IIb pancreatic cancer study
17 August 2026 - Israel-based clinical-stage biotechnology company Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF), which develops small-molecule drugs for oncological and inflammatory diseases, on Monday reported new preclinical findings s...
Acurx receives FDA conditional acceptance for ibezapolstat brand name
17 August 2026 - Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) disclosed on Monday that it has received conditional FDA acceptance for CIFBEZY, the proposed proprietary name for its lead antibiotic candidate ibezapolstat, alongsi...
Galmed reports positive preclinical results for Aramchol in prostate cancer
17 August 2026 - Biopharmaceutical and medical device company Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) on Monday reported preclinical results showing that Aramchol combined with enzalutamide produced a three- to four-fold increase in prostate cancer...
Azra AI and 4DMedical partner on lung health intelligence
17 August 2026 - Healthcare enterprise platform Azra AI and 4DMedical Limited (ASX: 4DX), a provider of quantitative lung imaging analytics, on Monday announced a strategic OEM and reseller partnership to provide health systems with enterprise-wide l...
AstraZeneca reports positive Phase III results for Tagrisso and Orpathys
17 August 2026 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday announced positive high-level results from the SAFFRON Phase III trial, showing Tagrisso (osimertinib) plus Orpathys (savolitinib) delivered statistica...